

SYNERGY Stent Investigator-Sponsored Research¹ **TIMELESS** - Healing/Endothelial Coverage at 3-Month with 3-Month DAPT Technical and SYNERGY Stent **Principal Investigator:** clinical success single arm registry Juan Granada, MD (absence in hospital MACE) 50 Patients Primary Endpoint Data Reported Vascular Healing and Vasomotion **Principal Investigator: SYNERGY Stent vs. Absorb BVS (RCT 1:1) Stephane Cook, MD** Enrollment 30 Patients Primary Endpoint 1 site Complete Real World SYNERGY Registry **Principal Investigator: SYNERGY Stent** single arm registry **Stephane Cook, MD** Data Reported 1000 Patients Primary Endpoint 3 sites **BIORESORT** - All Comers with Diabetes Substudy **SYNERGY Stent vs. Principal Investigator: Resolute Integrity[™] Stent vs.** Clemens von Birgelen, MD, Orsiro[™] Stent (RCT 1:1:1) PhD Enrollment Primary Endpoint 3450 patients Complete **SORT OUT VIII** - Real-World, All-Comers SYNERGY Stent vs. **Principal Investigators: BioMatrix NeoFlex[™] Stent**; Michael Maeng, MD and **OCT Healing substudy in 2800** patients at 1-month and Jens F Lassen, MD 2800 patients **Primary Endpoints** 3 sites Complete **SORT OUT VIII Imaging** - Real World, All comers Early Vessel Healing **Principal Investigators:** SYNERGY Stent vs. BioMatrix NeoFlex Michael Maeng, MD and **Stent; OCT Healing substudy in** 3M oct additional 160 patients at 1-month Jens F Lassen, MD Enrollment **Primary Endpoints** 160 patients Complete Reduced DAPT in Elderly SYNERGY Stent vs. BMS 1-month **Principal Investigator: DAPT** in elective patients **Olivier Varenne MD, PhD** and 6-months DAPT in ACS patients (RCT 1:1) Now Enrolling ~1200 patients 40 sites Multi-Vessel Disease **SYNERGY Stent single arm, compared Principal Investigator:** to historical CABG population; **Javier Escaned, MD IVUS** and FFR to be utilized Enrollment Primary Endpoint 400 patients Complete Endothelial Coverage and Neo-Atherosclerosis Compared to RI **Principal Investigator: SYNERGY Stent vs. 3**M 18M Giulio Guagliumi, MD **Resolute Integrity[™] Stent** % struts uncovered % struts uncovered Enrollment 90 patients **Primary Endpoints** Complete CELTIC BIFURCATION Coronary Bifurcation Study (Culottes Bifurcation Stenting) **Principal Investigator: SYNERGY Stent vs. Xience Xpedition™ Stent (RCT 1:1) David Foley, MD** 170 patients Primary Endpoint Now Enrolling 9 sites Left Main European RCT SYNERGY Stent vs. Xience™ **Principal Investigator:** Stent, (RCT 1:1); OCT healing **Robert-Jan van Geuns, MD** substudy at 3-months **Primary Endpoints** Now Enrolling 20 sites 818 patients **CONSISTENT CTO** • Safety And Efficacy of Sub-Intimal Stenting with SYNERGY in CTO **Principal Investigator: Prospective, multi-center, single arm** 12M Simon Walsh, MD Primary Endpoint 200 patients Now Enrolling 6 sites GREEK PLATELET STUDY - Platelet Activation And Evaluation of Platelets α2A-Ars And α2B-Ars **Principal Investigator: SYNERGY Stent vs. BMS historical comparator: Prof. George E. Investigate platelet gene expression and** protein levels of α 2A-ARs and α 2B-ARs in pts. **Kochiadakis, MD** with CAD, before and after stent implantation Now Enrolling Primary Endpoint 1 site 150 patients SYNERGY in Real World National Registry **Principal Investigators:** ~4,000 patients in 50,000 patient cohort, Giovanna Sarno, MD comparison to other DES Clinically driven restenosis & TLR at 12m, Early/late ST **Stefan James, MD** Enrollment ~4,000 patients Primary Endpoint Complete 29 sites Retrospective OCT observational study **Principal Investigators:** Single arm observational study assessing 3M tissue coverage and tissue characterization **David Foley, MD** % Stent Strut Coverage⁹ profile assessed by OCT at 3-months Robert Byrne, MD Data Being Reviewed Primary Endpoint 1 site 60 patients **ISAR RESORB** - RCT of SYNERGY and BVS **Principal Investigator: SYNERGY Stent vs BVS Scaffold Robert Byrne, MD and** (1:1 RCT), de-novo lesions Adnan Kastrati, MD (excluding LM & AMI) DOCE Now Enrolling Primary Endpoint 230 patients SYNERGY VS BVS IN CLINICAL PRACTICE -Real World Registry **Principal Investigator:** Clinical practice implications, Jose de la Torre Hernandez, SYNERGY (n=50) vs procedural resources, acute performance and MD and Javier Zueco, MD **BVS** (n=50) Registry complications

& stent malapposition assessed by OCT

OCT RESORBABLE POLYMER AND BVS - OCT assessment of SYNERGY and BVS **Principal Investigator:** % Strut coverage, neointimal thickening, Jose de la Torre Hernandez, MD at 6 months & 12 months

- Primary Endpoint 100 patients Complete
- 1. Boston Scientific is not responsible for the collection, analysis or reporting of the investigator-sponsored research output which is the sole responsibility of the investigators. Boston Scientific's involvement in investigator-sponsored research is limited to providing financial support for research that advances medical and scientific knowledge
- about our products. Safety and performance of the SYNERGY Coronary Stent System has not been established for use in patients with STEMI, chronic total occlusion, bifurcation, left main disease, and multi-vessel disease stenting. The SYNERGY Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic
- heart disease due to discrete de novo native coronary artery lesions. CE Mark Approved 2012. 2. For the SWEET Study MACE is defined as cardiac death, MI and TLR

100 patients

- 3. For the SYNTAX II study, MACCE is defined as: all-cause death; cerebrovascular event (stroke); documented myocardial infarction or all-cause revascularization.
- 4. For the CELTIC BIRFUCATION Study Clinical and Angiographic composite is defined as: Death, Myocardial Infarction, CVA (cerebrovascular events), Target Vessel Failure (Composite of Target Vessel Revascularization and Target Vessel Inadequacy); Definite or Probable stent thrombosis (ARC criteria); Binary angiographic restenosis
- 5. For the IDEAL-LM study, MACCE is defined as: all-cause death; stroke; myocardial infarction or ischemia driven target vessel revascularization. 6. Target Vessel Failure is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or cardiac death. 7. Primary endpoint for Greek Platelet Study is the postinterventional comparison of platelet activation gene expression and protein levels of α2A-ARs and α2B-ARs in patients with coronary
- 8. Primary endpoint for SCAAR registry: Clinically driven restenosis up to 1-year, TLR by PCI up to 1-year, Evaluate restenosis and stent thrombosis rates. # of sites: All patients undergoing PCI in Sweden from March 2013 until February 2015.
- 9. Primary endpoint for SYNERGY OCT in Bifurcations: Percentage of stent strut coverage at 3-months follow-up assessed by OCT for each visible strut segment.

artery disease before and after stent implantation. Follow-up examination & duration: Blood sampling at baseline and every 2 months for 1 year.

Enrollment

All trademarks are the property of their respective owners.